Search Within

Department of Medicine

Formats
  1. Journal Article (19593)
  2. Meeting Abstract (16038)
  3. Review (1150)
  4. Book Section (934)
  5. Editorial (610)
  6. Research Letter (314)
  7. Conference Paper (301)
  8. Guidelines (295)
  9. Correspondence (236)
  10. Miscellaneous (90)
  11. Book Whole (61)
Groups
  1. Solid Tumor Oncology Division (22321)
  2. Hematologic Malignancies, Division of (13278)
  3. Center for Hematologic Malignancies (11061)
  4. GSK Faculty (10646)
  5. Survivorship Research (9330)
  6. Division of Subspecialty Medicine (7535)

More Groups

People
  1. Robert Motzer (1248)
  2. Howard Scher (1132)
  3. Sergio Giralt (1069)
  4. Miguel-Angel Perales (943)
  5. Clifford Hudis (905)
  6. Jedd Wolchok (905)

More People

Years
  1. 2025 (1071)
  2. 2024 (2291)
  3. 2023 (2452)
  4. 2022 (2621)
  5. 2021 (2534)
  6. 2020 (2563)

More Years

Publications
  1. Journal of Clinical Oncology (6125)
  2. Blood (3722)
  3. Annals of Oncology (1398)
  4. Cancer Research (1238)
  5. Clinical Cancer Research (902)
  6. Biology of Blood and Marrow Transplantation (679)

More Publications

Publishers
  1. American Society of Clinical Oncology (6458)
  2. Elsevier Inc. (4216)
  3. American Society of Hematology (4003)
  4. American Association for Cancer Research (2896)
  5. Oxford University Press (2286)
  6. Nature Publishing Group (2111)

More Publishers

Results (39622)


Citation style sort is year ascending, and then by author or title. Author ascending is default.
  • Efficacy and safety of trastuzumab deruxtecan (T-DXd) in patients (pts) with HER2-expressing solid tumors: Results from the bladder cohort of the DESTINY-PanTumor02 (DP-02) study
    Meeting Abstract

    Wysocki, P. J.; Jung, K. H.; Oh, D. Y.; Doroshow, D. B.; Artamonova, E.; Mammatas, L.; Su, P. J.; Moiseyenko, V.; Penkov, K.; Stroyakovskiy, D.; more...
    Journal of Clinical Oncology (2024)

    Fulltext@MSK | Save
  • Pooled analysis by best confirmed response to trastuzumab deruxtecan (T-DXd) in patients (pts) with HER2+ metastatic breast cancer (mBC) from DESTINY-Breast-01,-02, and-03
    Meeting Abstract

    Saura, C.; CorteĢs, J.; Modi, S.; Kim, S. B.; Hamilton, E. P.; Hurvitz, S. A.; Krop, I. E.; Curigliano, G.; Iwata, H.; Im, S. A.; more...
    Journal of Clinical Oncology (2024)

    Fulltext@MSK | Save
  • Lete-cel in patients with synovial sarcoma or myxoid/round cell liposarcoma: Planned interim analysis of the pivotal IGNYTE-ESO trial
    Meeting Abstract

    D'Angelo, S. P.; Furness, A. J. S.; Thistlethwaite, F.; Burgess, M. A.; Riedel, R. F.; Haanen, J.; Noujaim, J.; Chalmers, A. W.; Pousa, Alpo; Chugh, R.; more...
    Journal of Clinical Oncology (2024)

    Fulltext@MSK | Save
  • GEMINI-Hepatobiliary: A phase 2 study of novel first-line immuno-oncology-based treatments in patients with advanced hepatobiliary cancers
    Meeting Abstract

    Zhou, J.; Cheng, A. L.; Ikeda, M.; Lim, H. Y.; Akce, M.; Qin, S.; Oh, D. Y.; Chan, S. L.; Xiang, J.; Qu, X.; more...
    Journal of Clinical Oncology (2024)

    Fulltext@MSK | Save
  • Comparison of clinical outcomes of stable disease with confirmed tumor reduction and RECIST partial response for tebentafusp in metastatic uveal melanoma (mUM)
    Meeting Abstract

    Ikeguchi, A.; Sato, T.; Butler, M. O.; Carvajal, R. D.; Sacco, J. J.; Shoushtari, A. N.; Hassel, J. C.; Nathan, P. D.; Piulats, J. M.; Johnson, D. B.; more...
    Journal of Clinical Oncology (2024)

    Fulltext@MSK | Save
  • Final overall survival results from phase 3 SPOTLIGHT study evaluating zolbetuximab + mFOLFOX6 as first-line (1L) treatment for patients (pts) with claudin 18 isoform 2 (CLDN18.2)+, HER2-, locally advanced (LA) unresectable or metastatic gastric or gastroesophageal junction (mG/GEJ) adenocarcinoma
    Meeting Abstract

    Shitara, K.; Van Cutsem, E.; Lordick, F.; Enzinger, P. C.; Ilson, D. H.; Shah, M. A.; Xu, R. H.; Lonardi, S.; Yamaguchi, K.; Hung, Y. P.; more...
    Journal of Clinical Oncology (2024)

    Fulltext@MSK | Save
  • Impact of exposure on outcomes with enfortumab vedotin in patients with locally advanced or metastatic urothelial cancer
    Meeting Abstract

    Petrylak, D. P.; Chia, Y. L.; Yu, E. Y.; Powles, T.; Flaig, T. W.; Loriot, Y.; O'Donnell, P. H.; Heath, E. I.; Kojima, T.; Park, S. H.; more...
    Journal of Clinical Oncology (2024)

    Fulltext@MSK | Save
  • Botensilimab plus balstilimab in microsatellite stable metastatic colorectal cancer: Assessing efficacy in non-liver metastatic sites
    Meeting Abstract

    Fakih, M.; Bullock, A. J.; Schlechter, B. L.; Tsimberidou, A. M.; Messersmith, W. A.; Pimentel, A.; Balmanoukian, A. S.; Sanborn, R. E.; Segal, N. H.; Bockorny, B.; more...
    Journal of Clinical Oncology (2024)

    Fulltext@MSK | Save
  • Long-term efficacy and safety of larotrectinib in patients with TRK fusion lung cancer
    Meeting Abstract

    Drilon, A. E.; Kummar, S.; Lin, J. J.; Tan, D. S. W.; Moreno, V.; Leyvraz, S.; Dubashi, B.; Haresh, K. P.; Burcoveanu, D. I.; Neu, N.; more...
    Journal of Clinical Oncology (2024)

    Fulltext@MSK | Save
  • Evaluation of the study of control arms in randomized clinical trials of cancer
    Meeting Abstract

    Jain, S. K.; Zauderer, M. G.; Sethi, T.; Schoen, M. W.; Rubinstein, S.; Nguyen, R. H. T.; Nagpal, S.; Mohan, S.; Madireddy, S.; Lythgoe, M.; more...
    Journal of Clinical Oncology (2024)

    Fulltext@MSK | Save